drugset / Trial / NCT02753062
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, prospective, single arm phase 2 trial of the combination of bendamustine and rituximab in patients with PTLD, monomorphic cluster of differentiation antigen 20(CD20) positive DLBCL. The investigators want to investigate the efficacy and safety of the combination of bendamustine and rituximab in patients with previously untreated PTLD, monomorphic CD20 (+) diffuse large B-cell lymphoma.
Timeline
- Start
- 2015-08
- Primary completion
- 2018-08
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 120 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1400 mg | Subcutaneous |